Trial reportBlood2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06339255 (A Multicenter Prospective Observational Study on Chimeric Antigen Receptor), which is not on this map. Cited by 225 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 3 pooled it
18.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting
Who cites it
225 citing papers in PubMed, 3 syntheses or guidelines pooled it, 327 citations in OpenAlex.
- Pooled it
- Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews · 2021Pooled it
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.Journal for immunotherapy of cancer · 2026Trial
- Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.Journal for immunotherapy of cancer · 2025Trial
- Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.Blood advances · 2022Trial
- Trial
- Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.Blood advances · 2026Article
- Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.Bone marrow transplantation · 2026Article
- Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Cancer research and treatment · 2026Article
- Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Review
- Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Bone marrow transplantation · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies.Molecular cancer · 2026Review
- Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies.Molecular therapy. Advances · 2026Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 3 institutions in 2 countries.
Alexandre V HirayamaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0001-7980-3882
Jordan GauthierClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-5769-8409
Kevin A HayClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-9398-2677
Jenna M VoutsinasClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Qian WuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Ted GooleyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Daniel LiJuno Therapeutics, Seattle, WA; and.
Sindhu CherianDepartment of Laboratory Medicine and.
Xueyan ChenDepartment of Laboratory Medicine and.
Barbara S PenderClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Reed M HawkinsClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0001-8611-2588
Aesha VakilClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Rachel N SteinmetzClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0001-8847-112X
Utkarsh H AcharyaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-5920-2796
Ryan D CassadayClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-3424-2425
Aude G ChapuisClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-9574-5448
Tejaswini M DhawaleDepartment of Medicine, University of Washington, Seattle, WA.ORCID 0000-0003-0163-2061
Paul C HendrieDepartment of Medicine, University of Washington, Seattle, WA.ORCID 0000-0003-1902-5972
Hans-Peter KiemClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0001-5949-4947
Ryan C LynchClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0001-6703-0894
Jorge RamosClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Mazyar ShadmanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Brian G TillClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-4718-8288
Stanley R RiddellClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-4688-9920
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-8477-6919
Cameron J TurtleClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-4722-4461
University of Washington · USFred Hutch Cancer Center · USUniversity of British Columbia · CA
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MCORE--VECTOR PRODUCTIONP30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERNSTEIN, IRWIN D · 1999 to 2014
$14.9MStem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1MTargeted therapy of B cell malignances with CAR-T cells of defined compositionR01CA136551 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JENSEN, MICHAEL C, RIDDELL, STANLEY R. · 2009 to 2018
$5.5MFHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600kNCI NIH HHS P30 CA015704NCI NIH HHS R01 CA136551NIDDK NIH HHS P30 DK056465NIDDK NIH HHS U54 DK106829NIH HHS S10 OD020069
Abstract
Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS) in patients with aggressive NHL treated with cyclophosphamide and fludarabine lymphodepletion followed by 2 × 10
Indexed as
Antigens, CD19Antineoplastic Combined Chemotherapy ProtocolsCell- and Tissue-Based TherapyCombined Modality TherapyCyclophosphamideFemaleFollow-Up StudiesHumansImmunotherapyLymphocyte DepletionLymphoma, Non-HodgkinMaleMiddle AgedPrognosisReceptors, Antigen, T-CellSurvival RateAntigens, CD19CyclophosphamidefludarabineReceptors, Antigen, T-CellVidarabine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06339255ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.